AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), is partnering with Ono Pharmaceutical Co., Ltd. to manufacture new biopharmaceuticals at the clinical development stage. ONO is a R&D-oriented pharmaceutical company committed to discovering and developing innovative drugs.
 
“We are very pleased to initiate this partnership with ONO,” said Mark Womack, CBO of AGC Biologics. “We look forward to closely collaborating with ONO to manufacture innovative and important therapies.”
 
AGC Biologics’ global network spans three continents, with cGMP-compliant facilities in Seattle, WA; Boulder, CO; Copenhagen, Denmark; Heidelberg, Germany; Milan and Bresso, Italy and Chiba, Japan. Their best in class services include development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells.